Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipeline
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)
Latest
2 stories